ABSTRACT: Next-generation sequencing has greatly accelerated the search for disease-causing defects, but even for experts the data analysis can be a major challenge. To facilitate the data processing in a clinical setting, we have developed a novel medical resequencing analysis pipeline (MERAP). MERAP assesses the quality of sequencing, and has optimized capacity for calling variants, including single-nucleotide variants, insertions and deletions, copynumber variation, and other structural variants. MERAP identifies polymorphic and known causal variants by filtering against public domain databases, and flags nonsynonymous and splice-site changes. MERAP uses a logistic model to estimate the causal likelihood of a given missense variant. MERAP considers the relevant information such as phenotype and interaction with known disease-causing genes. MERAP compares favorably with GATK, one of the widely used tools, because of its higher sensitivity for detecting indels, its easy installation, and its economical use of computational resources. Upon testing more than 1,200 individuals with mutations in known and novel disease genes, MERAP proved highly reliable, as illustrated here for five families with disease-causing variants. We believe that the clinical implementation of MERAP will expedite the diagnostic process of many disease-causing defects.
Introduction
Since the introduction of next-generation sequencing (NGS) techniques, there have been many articles on single gene defects underlying known or novel genetic diseases [Bamshad et al., 2011; Najmabadi et al., 2011; Rauch et al., 2012; Yu et al., 2013] . Such gene defects are not confined to familial cases; de novo and inherited mutations explain a significant portion of common and rare diseases, particularly in outbred Western populations [Vissers et al., 2010] . Given the growing awareness that the total number of monogenic disorders is much larger than previously assumed and the rapidly increasing number of known gene defects [Boycott et al., 2013] , there is a growing need to implement NGS techniques in the clinic as diagnostic tools [Hu et al., 2009; Mamanova et al., 2010; Hu et al., 2011; Bainbridge et al., 2013] . While diagnostic tests combining targeted exon enrichment and NGS to rule out mutations in several dozen to more than 1,000 disease genes are gaining ground, the clinical implementation of whole-exome or whole-genome sequencing still lags behind. This is a major problem for the molecular diagnosis of known diseases and for the identification of hitherto unknown ones, as large-scale medical genome sequencing and central storage and comparison of the clinical and sequence information are crucially important for identifying disease-causing mutations in a sea of functionally neutral sequence variants. Whole-exome or genome sequencing may generate unsolicited genetic information, which is considered as an issue even though the same is true for a wide variety of established diagnostic procedures. More serious problems hampering the introduction of medical genome sequencing relate to the performance of available NGS techniques, the complexity and low concordance of variant-calling pipelines, and the identification and prioritization of potentially disease-causing sequence variants [O'Rawe et al., 2013] .
Here, we describe a novel, easy-to-install and to-use medical resequencing analysis pipeline (MERAP; https://sourceforge. net/projects/merap) that compares favorably with several of the existing ones in various respects and is designed as a one-stop solution for clinical applications and for research laboratories with limited bioinformatics support. It consists of eight sequentially operating software modules that interact with several databases to generate a prioritized shortlist of plausible disease-causing mutations, as shown in Figure 1 .
Medical Resequencing Analysis Pipeline
MERAP is a comprehensive solution for handling the NGS data, evaluating the performance, and for detecting, filtering, annotating, and prioritizing sequence variants. The pipeline is compatible with a variety of enrichment platforms used in combination with Illumina sequencers, and it requires only minor adjustment for use in combination with other NGS systems.
MERAP uses SOAP2 as the default mapping tool for aligning the raw sequencing reads to the human reference genome, but is also compatible with other tools after minor adjustment [Li et al., 2009b] . Its alignment report provides elementary information such as total output (Gb), percentage of bases reaching the Q20 quality threshold Figure 1 . Flowchart and components of MERAP. MERAP is composed of eight software modules, namely, SNVFinder for calling SNVs and generating the base-wise sequencing depth, IndelFinder for calling indels and other structural variants, CNVFinder for calling CNVs, SSFinder for defining cryptic splice sites, Coverage for evaluating sequencing performance by coverage information, VariantPacker for packing variants from a cohort into a general variant list for subsequent annotation and prioritization, Annotation for filtering the variants and annotating by gene models, and Prioritize for prioritizing candidate mutations by considering their pathogenicity and other relevant information. Boxes connected by arrows show the direction of the analytical procedure. The color of each box is matched with the software responsible for each specific step.
[ Cock et al., 2010] , percentage of aligned reads, and so on. The report also lists the coverage and sequencing depth for each gene, its exons, coding sequences, and its transcript. In order to evaluate the evenness of the sequencing depth, a correlation between coverage and sequencing depth is provided for the entire target region (Supp. Table S1 , also see the Supporting Information for algorithm details of coverage).
Functionality
Calling sequence variants involves three different software modules, starting with SNVFinder which focuses on single-nucleotide variants (SNVs). Characteristically, heterozygous SNVs are called if 30%-70% of the nonredundant reads carry identical sequence variants, whereas the other reads correspond to the wild-type sequence. The quality score of each SNV reflects the sequencer-generated Phred-like score (i.e., the sequencing chip image quality) as well as the positional mappability (the probability of a read being aligned to the cognate region) [Ewing and Green, 1998 ]. The corrected quality score is rescaled to the customary range of 0-40. Artificial SNVs due to nearby indels are predicted and removed. SNVFinder can automatically accommodate itself to different read length (allowed in the same batch), quality format (both Illumina format and Sanger format are allowed), and allows for both redundant and nonredundant reads (see Supporting Information for algorithm details of SNVFinder.pl; see Supp. Figs. S1 and S2).
Copy-number variant (CNV) calling is based on the detection of exons with a significantly elevated or reduced number of overlapping sequence reads. Normalization is performed to compensate for different exon lengths, GC-content, and possible gaps due to the enrichment of target sequences, using preferably more than 20 samples in a batch. After log2 transformation, a value of zero corresponds to the normal diploid state, with significantly higher or lower values for duplications and deletions, respectively (see Supp. Fig. S3 ). In practice, even after stringent normalization, the variable sequencing depth renders this method unsuitable for detecting indels that involve only a single exon. Since most indels detected correspond to known CNVs, MERAP filters out known and repeatedly occurring CNVs and retains only indels that encompass two or more adjacent exons. The price for this is minimal, as most of the smaller CNVs can be identified by another MERAP module (see below). Further details concerning the CNVFinder algorithm are provided in the Supporting Information.
IndelFinder, another subroutine of MERAP, detects indels and other complex genomic rearrangements. As shown in Figure 2 , the are uniquely mapped to the reference genome; after pattern match and extension, the breakpoints are defined, which are used to define the events of insertion, deletion, and rearrangement. B: Only one substring (blue) is uniquely mapped to the reference genome; the other substring is shortened (red) and mapped to the 10-kb genomic vicinity of the mapped substring (blue). After pattern matching and extension, the breakpoints are established and the molecular details of the rearrangement are inferred. C: Only one substring (blue) is uniquely mapped to the reference genome; after pattern match and extension, the breakpoint is defined; reads with the same breakpoint from the same direction are collected to find the one with longest unidentified sequence. If the same breakpoint is identified from the other direction, and if the de novo assembled sequence aligned to the reference genome with a large insertion shows the same breakpoints, a large insertion is thus defined. The sequences flanking large insertions are aligned to RepBase to trace their origins.
underlying algorithm combines a split-read strategy with a de novo assembly approach. Two (e.g., 36 bp) substrings are extracted from the termini of each unaligned read and mapped to human genome. If both substrings can be uniquely mapped, they will be used as anchors for subsequent analyses. If only one substring can be unambiguously mapped, the other substring will be shortened to 10 bp and used to search in silico for a complementary sequence within of a radius of 10 kb around the mapped substring. Then, the length of the two anchors is increased and that of the insert separating them is reduced by pattern match and extension through comparison with the reference genome. Subsequently, the positions of the two anchors and the size of the insert are used to infer the presence of insertions, deletions, and other rearrangements including complex substitutions.
To identify insertions that cannot be accommodated on a single sequence read, IndelFinder starts out from reads harboring only one anchor to recover flanking sequences from both sides of the insertion. With these sequences as probes, de novo assembly is then performed on the pool of unaligned reads, resulting in a series of contigs that are then aligned to the human reference genome by BLAT (http://genome.ucsc.edu/FAQ/FAQblat.html). Medium to large size insertions are also mapped to the repeat sequence database (RepBase, http://www.girinst.org/repbase/) to characterize their origin (see Supporting Information for algorithm details of IndelFinder). In practice, deletions as large as 25,859 bp have been detected in this way; full-length sequences could be inferred for insertions as large as 400 bp; and complex rearrangements such as tandem duplications ranging in size from 40 to 1,178 bp have been identified.
Typically, MERAP detects 0.82 variant per 1 kb transcript regions, among which the percentages of SNV, small Indel, other variants such as large insertion, tandem duplication, and CNV, are 85.4, 12.2, and 2.4, respectively. All variants called by MERAP are presented in a format complying with the nomenclature for the description of sequence variants (Human Genome Variation Society [HGVS] , http://www.hgvs.org/mutnomen/). MERAP variant calling has been evaluated by conventional Sanger sequencing. In practice, >99.9% of the variants called by MERAP could be confirmed, and false-positive results were only obtained for variants supported by less than five reads. We evaluated the sensitivity of MERAP variant calling by comparison with known variants from Affymetrix genotyping array and found the concordance to be as high as 99.5%. The high reliability of MERAP variant calling is also reflected by the consistent appearance of highly recurrent (>10% in cohort) variants in public databases including dbSNP, 1000 Genome, and ESP 6500 exomes [Sherry et al., 2001; Altshuler et al., 2012; Fu et al., 2013] . All variants identified in a cohort are packed by VariantPacker into a general variant list for the subsequent annotation and prioritization.
All variants identified by MERAP are first filtered through comparison with more than 126,000 disease-associated variants extracted from Human Gene Mutation Database (HGMD) and Online Mendelian Inheritance in Man (OMIM) to identify known disease-causing mutations. In order to filter out neutral variants, MERAP uses up to one million entries from db-SNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), 1000 Genome (http://www.1000genomes.org/), and NHLBI Exome Sequencing Project (ESP, http://evs.gs.washington.edu/EVS/) as databases. MERAP does not only consider matches in the databases, but also their frequency in the population and in the cohort studied. For example, homozygosity for mutations causing recessive disorders should not occur in healthy controls, and the frequency of heterozygotes should not exceed one or few percent; and mutations causing severe dominant disorders should not be observed at all. More than 90% of the variants can be ruled out in this way.
For translating DNA variants into amino acid changes and for assessing the functional relevance of nonsynonymous or splice-site changes, MERAP uses RefSeq genes (http://www.ncbi. nlm.nih.gov/refseq/) as reference, because of their nonredundancy and consistency. Nonsynonymous changes are described in terms of gene ID, base change, protein change, genomic coordinate, transcript coordinate, protein coordinate, protein length, affiliated with gene description from the Human Gene Nomenclature Committee (HGNC, http://www.genenames.org/) ( Fig. 3; Table 1 ). MERAP identifies changes destroying conventional splice sites (2 bp flanking sequences of exons) or introducing novel splice sites (see Supporting Information for algorithm details of SSFinder).
To assess the pathogenicity of missense mutations, MERAP generates a single score that is based on Logit modeling and integrates the results of seven different algorithms, including the Grantham score (codon replacement conservation based on chemical dissimilarity) [Grantham, 1974] , phyloP (base replacement There are 24 fields shown in MERAP results, including the sample ID, the variant information, the reads number supporting the variant, the allele percentage of the variant, the quality of the call, the variant frequency in cohort, the variant position in terms of the linkage intervals, the HGMD match, the OMIM match, the dbSNP match, the 1000 Genome match, the ESP6500 match, the Grantham score, the phyloP score, the GERP score, the SIFT score, the PolyPhen2 score, the MutationTaster score, the CDD score, the Logit score, the LOF score, the interaction partner, the known disease, and the inheritance model. conservation) [Pollard et al., 2010] , GERP (base replacement conservation) [Davydov et al., 2010] , SIFT (amino acid residue conservation) [Ng and Henikoff, 2003 ], PolyPhen2 (various physical and comparative parameters) [Adzhubei et al., 2010] , MutationTaster (integrated evaluation of base and amino acid conservation) [Schwarz et al., 2010] , and the Conserved Domains Database (CDD, http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml; details of the scoring algorithm are provided in the Supporting Information). With empirical false discovery rate cutoffs, the integrated Logit scores allow for dichotomized pathogenicity predictions even if SIFT, PolyPhen2, and MutationTaster predictions do not coincide, as is often the case. To calibrate this integrated score, we collected 7,703 disease-causing (DM) missense mutations from HGMD, all with heterozygote frequencies of <1% in the 1000 Genome or ESP6500 databases, as well as 3,520 neutral missense variants that occur in homozygous form in the 1000 Genome and ESP6500 databases, with allele frequencies exceeding 10%. The seven aforementioned algorithms generate the numerical predictions for the case and control sets, which are then converted into ranks. A Logit model was fitted to optimize the discrimination between case and control sets. Its receiver operating characteristic (ROC) curve shows high performance of the model (the area under the curve [AUC] = 0.95) and its robustness by resampling without replacement (Fig. 4) . Compared with other pathogenicity scores combining multiple predictors, advantages of the MERAP Logit score model include the availability of stringent training sets and the use of ranks instead of numerical values [Calabrese et al., 2009; Li et al., 2009a; Adzhubei et al., 2010; Gonzalez-Perez and Lopez-Bigas, 2011; Lopes et al., 2012; Frousios et al., 2013; Sifrim et al., 2013; Kircher et al., 2014] . As shown by the ROC curves, MERAP performs as well as eXtasy and CADD, outperforms CoVEC and Condel, and is significantly superior to CAROL, PolyPhen2, SNPs&GO, and MutPRED (for further information about the annotation algorithm and details of Logit modeling and ROC evaluation, see Supporting Information). Even after filtering and annotation, we are typically left with several to dozens of candidate mutations for each case. When cohorts of patients with the same ethnicity are studied, information on the proportion of homozygotes and heterozygotes carrying a particular variant is also useful for detecting population-specific polymorphisms (see Table 1 ). MERAP tracks candidate genes reported to harbor homozygous loss-of-function (LOF) variants in healthy individuals, which applies to >1% of the human genes. If more than three independent truncating variants are observed in >10 of the exomes listed in the 1000 Genome and ESP6500 databases, the relevant gene is flagged as LOF tolerant.
To facilitate the choice between few remaining candidate genes, MERAP also provides a list of˜3,000 known disease genes extracted from OMIM (http://www.ncbi.nlm.nih.gov/omim), ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/), and HGMD (http://www.hgmd.org/), as well as ß8,000 associated disorders and their symptoms. For novel candidate genes without prior link to disease, MERAP offers information on their interaction with known disease genes, based on data from Biogrid (http://thebiogrid.org/) and IntAct (http://www.ebi.ac.uk/intact/). The rationale is that genes implicated in clinically similar disorders tend to cluster in gene or protein interaction networks. Further details about the prioritization algorithm are provided in Supporting Information. A practical example illustrating the entire MERAP workflow and outcome is given in Table 1 .
Performance
MERAP is faster than other sequence analysis pipelines, and its computational requirements are modest. For example, on a server with 48 CPUs sharing 248Gb RAM, MERAP managed to process 221 WES samples (>60× mean coverage) and to complete the analysis within 4 days (92 hr). For smaller targets, the turnover was even much higher (see Supp. Table S1 ). For example, it took MERAP only 17 hr to screen 195 samples for mutations in 520 genes implicated in severe related to recessive childhood disorders birth defects [Bell et al., 2011] , and no more than 11 hr to analyze 60 individuals for mutations in a total of 1,222 disease genes, including most genes that have been linked to intellectual disability so far. For WES with >60× mean coverage, MERAP necessitates only 60 Gb RAM. MERAP has been designed for laboratories with limited infrastructure and resources for DNA sequence analysis. With its optimized default parameters and automatic links to all relevant databases, it can be downloaded and installed within 1 day (https://sourceforge.net/projects/merap), with minimal manual intervention.
To compare its performance with that of the widely used Genome Analysis Tool Kit (GATK) [DePristo et al., 2011] , we have analyzed WES results from 22 unrelated individuals with both pipelines, focusing on SNVs and indels. For MERAP and GATK, average processing times were 5 and 18 hr, respectively. 98% of the SNVs called by MERAP were also detected by GATK, whereas 75% of the indels identified by MERAP and 88% of GATK-identified indels were shared (see Supp. Fig. S4 ). It is of note that that one-third of the indels exclusively identified by MERAP correspond to known db-SNP entries, suggesting that at least some of the indels unique to MERAP in this study are real. For further details concerning the relative performance of MERAP and GATK, see the Supporting Information. The comparison with another SNV caller, VarScan, was conducted based upon the same dataset [Koboldt et al., 2009] . About 98.5% of SNVs identified by MERAP were also called by VarScan, whereas 99% of SNVs called by VarScan were identified by MERAP. The comparison with another indel caller, Pindel, was implemented based on the same dataset [Ye et al., 2009] . More than 95% of the indels called by Pindel could be found by MERAP but only 66% of the indels called by MERAP can be identified by Pindel. Up to 39% of the indels uniquely called by MERAP were variants listed in dbSNP. MERAP was also compared with CNVnator for identifying unique CNVs from the aforementioned dataset [Abyzov et al., 2011] . MERAP called on average 12 multiple-exon-spanning CNVs for each sample, 90% of which could also be identified by CNVnator. Seven CNVs on average were exclusively identified by CNVnator, most of which were deletions, but when we randomly picked three such CNVs and did quantitative PCR, none of them could be confirmed.
Discussion
Since 2008, we have used NGS techniques to process and analyze more than 1,200 human DNA samples (Supp . Table S3 ). In the course of this work, which enabled us to identify many dozen novel disease genes, we have developed several novel sequence alignment and analysis tools. Improved versions of these tools have now been linked to form MERAP, an integrated sequence analysis pipeline that provides a one-stop solution for identifying disease-causing mutations, for example, in a clinical setting. MERAP was instrumental in the reanalysis of numerous previously unsolved cases, and in the vast majority of cases that we had considered as solved, it confirmed our previous conclusions (Supp . Table S3 ). Moreover, it turned out to be a major asset for the investigation of more than 800 novel families with autosomal-recessive ID, autosomal-dominant ID, and X-linked ID Kahrizi et al., 2011; Najmabadi et al., 2011; Pak et al., 2011; Rafiq et al., 2011; Ropers et al., 2011; Schraders et al., 2011; Strobl-Wildemann et al., 2011; Huang et al., 2012; Zanni et al., 2012; Bainbridge et al., 2013; Dreha-Kulaczewski et al., 2013; Hirata et al., 2013; Lesca et al., 2013; Puttmann et al., 2013; Belet et al., 2014; de Brouwer et al., 2014; Larti et al., 2014; Masurel-Paulet et al., 2014; Philips et al., 2014] , as illustrated below for five of these that were found to carry defects in known or novel plausible candidate genes (see Supporting Information; Supp. Figus. S5-S9; Supp. Table S4 ).
MERAP can be retrieved from https://sourceforge.net/ projects/merap. It includes eight software programs, the relevant databases as well as manuals. NGS data mentioned in this paper can be retrieved from the Sequence Read Archive (SRA, http://www.ncbi.nlm.nih.gov/sra) under the accession numbers SRA036250. The aforementioned list of 1,222 genes for severe recessive childhood disorders and intellectual disability is available upon request. Most inherited disorders are genetically heterogeneous, and for some, the heterogeneity is overwhelming. For example, more than 700 different genes have been implicated in severe forms of intellectual disability (ID) (extracted from the latest version of HGMD [version 4, 2013] and OMIM [February, 2014] ), and there is reason to believe that the total number of ID genes will run into the thousands, most of which have not been identified yet [Ropers, 2010] . This strongly argues for introducing medical genome sequencing as standard diagnostic procedure, which in turn necessitates sequence analysis tools that are adapted to the needs of diagnostic laboratories with limited bioinformatics experience and infrastructure. MERAP has been developed to meet the rapidly growing demand for fast, easy to install, and user-friendly pipelines enabling the search for clinically relevant mutations in whole exomes or whole genomes, but also in defined segments of the human genome that can be isolated by targeted enrichment. Given its superior sensitivity and specificity, it should be equally useful for large, more experienced groups.
While in the current version of MERAP, settings have been optimized for its present task, future versions will enable users to fine-tune them at will to meet specific demands. Also, there will be room for implementing additional algorithms for pathogenicity prediction and for other adjustments by individual users. Finally, future versions of MERAP will be adapted to handle much larger data sets, for example, through further improvement of the processing efficiency and by implementing data compression.
